Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer
Muhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer.
This week, CancerNetwork® spoke with Muhammad Niazi, MD, resident in internal medicine at Staten Island University Hospital, and Alexander Bershadskiy, MD, attending physician at Staten Island University Hospital, about a meta-analysis published in ONCOLOGY® titled, “Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.”
The final analysis evaluated 3 randomized clinical trials. A fixed model showed a statistically significant improvement in overall survival for patients with metastatic castration-resistant prostate cancer treated with PARP inhibitors.
The authors provided a detailed background on PARP inhibitors and further detailed the results of this research, focusing on increased survival with PARP inhibitor treatment for this patient population.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
Data Support Early Genetic Testing in HRR+ mCRPC Managed With Olaparib
January 27th 2024Testing for HRR status prior to a diagnosis of metastatic castration-resistant prostate cancer may allow for earlier treatment and potentially greater clinical benefit with olaparib, according to Daniel J. George, MD.
